Effects of pioglitazone on nonalcoholic steatohepatitis in a patient with anorexia nervosa: A case report

Experimental and Therapeutic Medicine

Volumn 7, Issue 4, 2014, Pages 811-815

  Ohno, Tomohiko ^a   Nishigaki, Yoichi ^b   Yamada, Tetsuya ^b   Wakahara, Yuko ^c   Sakai, Hiroyasu ^a   Yoshimura, Kotaro ^c   Shimizu, Masahito ^a   Usui, Toshio ^c   Saito, Masaya ^c   Yasuda, Ichiro ^a   Tsurumi, Hisashi ^a   Tomita, Eiichi ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Gifu Municipal Hospital   (Japan)

^c Seki Chuo Hospital   (Japan)

Author keywords

Malnutrition; Pioglitazone; Steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GLYCYRRHIZIC ACID DERIVATIVE; PIOGLITAZONE; PREDNISOLONE; STRONGER NEO MINOPHAGEN C; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

AGED; ANOREXIA NERVOSA; ARTICLE; BODY MASS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRY SKIN; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAABDOMINAL FAT; JAUNDICE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION; MALNUTRITION; NONALCOHOLIC FATTY LIVER; SKIN TURGOR; TOTAL PARENTERAL NUTRITION; UREA NITROGEN BLOOD LEVEL;

EID: 84896736765     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1509     Document Type: Article

References (28)

1. Lucas AR, Crowson CS, O'Fallon WM and Melton LJ III: The ups and downs of anorexia nervosa. Int J Eat Disord 26: 397-405, 1999.
2. Tomita K, Haga H, Ishii G, et al: Clinical manifestations of liver injury in patients with anorexia nervosa. Hepatol Res: July 11, 2013 (Epub ahead of print).
3. Kuboki T, Nomura S, Ide M, Suematsu H and Araki S: Epidemiological data on anorexia nervosa in Japan. Psychiatry Res 62: 11-16, 1996.
4. Sakada M, Tanaka A, Ohta D, et al: Severe steatosis resulted from anorexia nervosa leading to fatal hepatic failure. J Gastroenterol 41: 714-715, 2006.
5. Ludwig J, Viggiano TR, McGill DB and Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438, 1980.
6. Sanyal AJ; American Gastroenterological Association: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123: 1705-1725, 2002.
7. Rautou PE, Cazals-Hatem D, Moreau R, et al: Acute liver cell damage in patients with anorexia nervosa: a possible role of starvation-induced hepatocyte autophagy. Gastroenterology 135: 840-848, 2008.
8. Narayanan V, Gaudiani JL, Harris RH and Mehler PS: Liver function test abnormalities in anorexia nervosa - cause or effect. Int J Eat Disord 43: 378-381, 2010.
9. Dowman J, Arulraj R and Chesner I: Recurrent acute hepatic dysfunction in severe anorexia nervosa. Int J Eat Disord 43: 770-772, 2010.
10. Promrat K, Kleiner DE, Niemeier HM, et al: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51: 121-129, 2010.
11. Belfort R, Harrison SA, Brown K, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297-2307, 2006.
12. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419, 1999.
13. Seidell JC: Obesity, insulin resistance and diabetes - a worldwide epidemic. Br J Nutr 83 (Suppl 1): S5-S8, 2000.
14. Smink FR, van Hoeken D and Hoek HW: Epidemiology of eating disorders: incidence, prevalence and mortality rates. Curr Psychiatry Rep 14: 406-414, 2012.
15. Osifo BO and Bolodeoku JO: Serum aspartate and alanine aminotransferase activities in protein energy malnutrition. Enzyme 28: 300-304, 1982.
16. Meinhardt NG, Souto KE, Ulbrich-Kulczynski JM and Stein AT: Hepatic outcomes after jejunoileal bypass: is there a publication bias? Obes Surg 16: 1171-1178, 2006.
17. Suzaki A, Miura H, Takazoe M, Hamada T and Kitamura S: Nonalcoholic steatohepatitis due to Crohn disease: a lethal case report. Nihon Shokakibyo Gakkai Zasshi 100: 1212-1218, 2003 (In Japanese).
18. Furuta S, Ozawa Y, Maejima K, et al: Anorexia nervosa with severe liver dysfunction and subsequent critical complications. Intern Med 38: 575-579, 1999.
19. Aithal GP, Thomas JA, Kaye PV, et al: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135: 1176-1184, 2008.
20. Tomita K, Azuma T, Kitamura N, et al: Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126: 873-885, 2004.
21. Hallakou S, Doaré L, Foufelle F, et al: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46: 1393-1399, 1997.
22. Kletzien RF, Clarke SD and Ulrich RG: Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41: 393-398, 1992.
23. Laplante M, Festuccia WT, Soucy G, et al: Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 55: 2771-2778, 2006.
24. Watkins PB: Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 33: 1-5, 2005.
25. Wang H, Khaoustov VI, Krishnan B, et al: Total parenteral nutrition induces liver steatosis and apoptosis in neonatal piglets. J Nutr 136: 2547-2552, 2006.
26. Matsumoto T, Yamasaki S, Arakawa A, et al: Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatits. Pathol Int 57: 388-389, 2007.
27. Leuschner UF, Lindenthal B, Herrmann G, et al: High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52: 472-479, 2010.
28. Tobari M, Hashimoto E, Yatsuji S, Torii N and Shiratori K: Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern Med 48: 739-746, 2009.